INBRAIN Neuroelectronics announced that Elucid and its team received oversubscribed Series D financing with key large strategic investors.
Public source
Publisher name
Public post
Congrats to Elucid and team on this oversubscribed Series D financing with key large strategic investors. The financing and strategic investor involvement are an endorse…
Company
INBRAIN Neuroelectronics
High density and high resolution graphene intelligent neural systems for BCI therapeutics *FDA Breakthrough Designation*
- Industry
- Technology, Information and Internet
- Location
- Barcelona, ES
- Company size
- 51–200 employees
About INBRAIN Neuroelectronics
High density and high resolution graphene intelligent neural systems for central and peripheral Neuroelectronic applications. *FDA breakthrough Designation* Pioneering Precision Neurology
See moreLatest activity
Latest activity from INBRAIN Neuroelectronics
2 signals
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Elucid
Elucid closed an oversubscribed $55 million Series D financing round bringing its total funding to approximately $185 million.
Capital & Finance
NeuroBionics
NeuroBionics has been awarded a Phase II SBIR grant from the National Science Foundation (NSF) to advance its IO Fiber platform.
Capital & Finance
NeuraSignal
NeuraSignal noted that RapidPulse, Inc. raised a $48 million Series B funding round for their suction-based technology.
Capital & Finance
nubrain
nubrain is in talks for a $1.2B Series B funding round for XDOF three months after a $70M Series A funding round for teleoperation and sensor pipelines.
Capital & Finance
Elevage Medical Technologies